- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01937598
Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D
December 7, 2016 updated by: Michael A. Nauck
Antidiabetic Effects of Adding a DPP-4 Inhibitor (Sitagliptin) to Pre-Existing Treatment With an Incretin Mimetic (Liraglutide) in Patients With Type 2 Diabetes Treated With Metformin
Objectives: To quantify differences in control of glycemia (primary objective) and the secretion of endogenous incretin hormones (secondary objective) comparing sitagliptin or placebo added to pre-existing therapy with liraglutide and metformin
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a double blind, controlled, cross-over comparison of adding sitagliptin (or placebo) to pre-existing metformin+liraglutide therapy.
Patients with type 2 diabetes mellitus (T2DM) on pre-existing treatment with metformin (≥ 1500 mg/d) monotherapy or metformin plus liraglutide (1.2 mg/d) will be studied.
Patients on metformin monotherapy will, after screening and randomization, enter a run-in period of 2 weeks with the additional treatment of liraglutide (0.6 mg/d for 1 week followed by 1.2 mg/d for another week).
At the end of this 2 weeks therapy, a mixed meal challenge will take place, with the assessment of glucose and hormone responses (insulin, C-peptide, glucagon, GLP-1 [glucagon-like peptide-1], GIP (gastric inhibitory peptide) and gastric emptying as measured by 13C (carbon 13)-octanoate breath tests.
Prior to the meal tests, liraglutide will be administered at a dose of 1.2 mg per injection, which is the recommended dose for treatment.
Sitagliptin will be used at a dose of 100 mg, which is recommended for clinical use.
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bad Lauterberg, Germany, 37431
- Diabeteszentrum Bad Lauterberg
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed & dated written informed consent
- Male & female subjects with a diagnosis of type 2 diabetes mellitus according to ADA criteria at least 4 months prior to screening
- Medical history without major pathology (with the exception of type 2 diabetes) as judged by the investigator
- On a stable regimen of metformin for at least 1 month and liraglutide 1.2 mg for at least 1 week at the time-point of randomisation.
- Age: 25 - 75 years, both inclusive
- Body mass index (BMI): 22 - 40kg/m^2, both inclusive
- HbA1c ≥ 6.5 and ≤ 8.5% (≥ 7.0 and ≤ 8.5% for patients without previous liraglutide treatment)
- Female must be post-menopausal, surgically sterilized or practicing an effective birth control
Exclusion criteria
- Subjects with type 1 diabetes, maturity onset diabetes of the young (MODY) or secondary forms of diabetes such as due to pancreatitis
- Current or previous treatment with insulin therapy (except for treatment at diabetes' diagnosis, within a clinical trial, for surgical procedures or during an acute illness, and no insulin administration within the 6 months before screening)
- Treatment with any hypoglycaemic medication other than metformin and liraglutide within one month prior to screening
- Known of diabetic gastroparesis and / or prokinetic therapy
- Subjects that underwent surgery of the upper gastrointestinal tract
- Women who are pregnant, intending to become pregnant during the study period, currently lactating females, or women of child-bearing potential not using highly effective, medically approved birth control methods
- Any severe medical or surgical history of conditions likely to confound study assessments or study endpoints, for example but not limited to haemoglobinopathies, inflammatory bowel disease, cystic fibrosis, bariatric surgery and/or any surgery shortening the intestine, history of lactose intolerance, lactose- or glucose-galactose-malabsorption
- A suspicion of medullary thyroid cancer or a multiple endocrine neoplasia
- A personal or family history of medullar thyroid cancer or a multiple endocrine neoplasia
- Serious and/or unstable coronary heart disease (unstable angina, myocardial infarction within the preceding 6 months), congestive heart failure of New York Heart Association Class III or worse (severe limitation of physical activity; physical activity of low intensity resulting in fatigue, palpitation, or dyspnoea), second/third degree heart block, superior vena cava syndrome, uncontrolled hypertension, history of congenital QT-syndrome within family, history of stroke (within the preceding 6 months) or serious peripheral vascular disease
- History of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is symptomatic or requires treatment (grade 3), left bundle branch block, or asymptomatic sustained ventricular tachycardia are not allowed
- Marked diabetic complications: severe autonomic or sensory neuropathy including previously diagnosed gastroparesis; proliferative retinopathy
- Any respiratory disease leading to respiratory insufficiency and/or depression including but not limited to clinically significant: bronchial asthma, chronic obstructive pulmonary disease, that might impact to the breath test, as judged by the investigator
- Clinically significant vital signs including known bradycardia with pulse rate < 50/min or 12-lead ECG findings including QTc (corrected QT interval) > 450 msec for males or QTc > 470 msec for women
- Clinically significant abnormal haematology, biochemistry, lipids, or urinalysis or coagulation screening tests, as judged by the Investigator
- Moderate or severe renal dysfunction defined as an estimated creatinine clearance (MDRD equation) GFR (glomerular filtration rate) <50 ml/min.
- Clinical or laboratory evidence of hepatic dysfunction or disease; laboratory evidence defined as any of the following parameters: alkaline phosphatase, ALT , AST or bilirubin > 3x ULN (upper Limit of normal). Isolated mild rise in bilirubin considered to be due to Gilbert's condition is allowed
- Uncontrolled high blood pressure (DBP (diastolic blood pressure) > 95 mmHg and/or SBP (systolic blood pressure) > 160 mmHg), unless clearly documented to be white-coat hypertension
- History of any psychiatric condition that might impair the subject's ability to understand or to comply with the requirements of the study or to provide informed consent
- History of relevant drug and/or food allergies or a history of severe anaphylactic reaction
- Currently active or history of alcohol abuse (defined as an intake of more than 24 units of alcohol per week; one unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits) or drug addiction (including soft drugs like cannabis products)
- Use of concomitant medication which would be likely to interact with metformin, sitagliptin or liraglutide (according to the subject information leaflet). Participation in another study within the 3 months preceding screening or 5-half-lives of drug studied, whichever is longer, prior to study drug administration
- Malignancy within 5 years of study start, except for successfully treated local basal cell carcinomas
- Known to be positive for Hepatitis B surface antigen or Hepatitis C antibodies (or diagnosed with active hepatitis according to local practice)
- Subject who has donated or lost > 500 mL blood within 3 months prior to screening & has a Hb < 14 g/dl at screening
- History of hypersensitivity to the study drug or any of the excipients or to medicinal products with similar chemical structures
- Veins unsuitable for repeated venipuncture
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sitagliptin, then Placebo
|
Patients administered a single dose of placebo during a mixed meal challenge.
Subjects will be instructed to consume the mixed meal test within 20 minutes.
The exact start and stop time of the mixed meal test consumption will be recorded in the CRF.
The mixed meal test procedures will be identical for all subjects randomised in the study.
To detect the plasma glucose excursion after mixed meal test, plasma glucose will be closely monitored
Patients on metformin monotherapy will, after screening and randomization, enter a run-in period of 2 weeks with the additional treatment of liraglutide (0.6 mg/d for 1 week followed by 1.2 mg/d for another week) that will be continued for the entire duration of the study.
Other Names:
Patients administered a single dose of Sitagliptin during a mixed meal challenge.
|
Experimental: Placebo, then Sitagliptin
|
Patients administered a single dose of placebo during a mixed meal challenge.
Subjects will be instructed to consume the mixed meal test within 20 minutes.
The exact start and stop time of the mixed meal test consumption will be recorded in the CRF.
The mixed meal test procedures will be identical for all subjects randomised in the study.
To detect the plasma glucose excursion after mixed meal test, plasma glucose will be closely monitored
Patients on metformin monotherapy will, after screening and randomization, enter a run-in period of 2 weeks with the additional treatment of liraglutide (0.6 mg/d for 1 week followed by 1.2 mg/d for another week) that will be continued for the entire duration of the study.
Other Names:
Patients administered a single dose of Sitagliptin during a mixed meal challenge.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incremental Area Under the Plasma Glucose (BG) Concentration-time Profile (AUC)
Time Frame: 0 to 300 min post mixed meal test
|
Incremental area under the plasma glucose (BG) concentration-time profile (AUC) immediately before to 300 min after a mixed meal test.
In addition, the time course of BG values will be analysed with an ANCOVA model for repeated measurements with placebo baseline values as covariate.
Time points to create the curce were 0, 15, 30, 45, 60, 90, 120, 150, 180, 240 and 300 minutes post mixed meal test.
|
0 to 300 min post mixed meal test
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC Plasma Glucose
Time Frame: Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)
|
Incremental AUC from 0 to 300 min
|
Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)
|
AUC Insulin
Time Frame: Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)
|
Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)
|
|
AUC C-peptide
Time Frame: Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)
|
Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)
|
|
AUC Glucagon
Time Frame: Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)
|
Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)
|
|
AUC Total GLP-1
Time Frame: Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)
|
Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)
|
|
AUC Total GIP
Time Frame: Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)
|
Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)
|
|
AUC Active GLP-1
Time Frame: Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)
|
Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)
|
|
AUC Active GIP
Time Frame: Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)
|
Approximately 6 weeks (range 9 - 60 days / 8.5 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2013
Primary Completion (Actual)
April 1, 2014
Study Completion (Actual)
June 1, 2015
Study Registration Dates
First Submitted
August 27, 2013
First Submitted That Met QC Criteria
September 4, 2013
First Posted (Estimate)
September 9, 2013
Study Record Updates
Last Update Posted (Estimate)
January 30, 2017
Last Update Submitted That Met QC Criteria
December 7, 2016
Last Verified
December 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protease Inhibitors
- Incretins
- Dipeptidyl-Peptidase IV Inhibitors
- Liraglutide
- Sitagliptin Phosphate
Other Study ID Numbers
- 120-0569-DZBL-2012
- 2013-001764-35 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
-
University of Alabama at BirminghamUnited States Department of Defense; Loma Linda University; Brenda Davis Nutrition... and other collaboratorsCompletedType 2 Diabetes Mellitus
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States